Condition: ALL (Acute B-Lymphoblastic Leukemia) · Sponsor: Liping Dou
This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.
This description comes directly from the study's public registry record.
Lu Wang · 86-10-66937079 · wangludophine@163.com
Liping Dou, Dr. · lipingruirui@163.com
Always discuss trial participation with your own doctor first.
| Chinese PLA General Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07677878